HOME >> BIOLOGY >> NEWS
WSU scientist part of study seeking vaccines to combat potential bioterrorist attack

A research scientist at Wright State University is involved in a $1 million federal grant to combat a terrorist attack involving biological weapons.

Dawn Wooley, Ph.D., an associate professor in anatomy and physiology, is part of the Midwest Center of Excellence for Biodefense and Emerging Infectious Diseases Research.

"Our goal is to develop the diagnostic tools, therapeutics and vaccines that can be used to combat lethal agents or viruses and other infectious diseases identified by the Centers for Disease Control. We are particularly interested in agents that can be spread through the air," explained Wooley, who holds a doctorate from Harvard Medical School in virology, which is the study of viruses and viral diseases.

She became interested in this project after the terrorist attacks on Sept. 11, 2001, and subsequent anthrax scare. "My principal research work involves AIDS, but the threat involving bioterrorism is so great that I could not resist getting involved. This is so important to the United States and the world because some of these agents can kill people within a few days. Just think back to what the anthrax scare did to the postal service and you can realize how frightening a situation this can be."

The Midwest Center is a group of eight universities, including Wright State, which received funding from the National Institutes of Health. The University of Minnesota is the principal investigator and The Ohio State University is the co-principal investigator. The WSU research scientist is working with colleagues at both universities in her phase of the two-year project.

Wooley, who received initial funding for this project from Wright State, said the other participating institutions are the University of Cincinnati; University of Michigan; Indiana University; University of Illinois, Chicago; and Northwestern University.

The planning grant funds from NIH are related to a recently announced award of $350 mil
'"/>

Contact: Dawn Wooley
dawn.wooley@wright.edu
937-775-4993
Wright State University
15-Oct-2003


Page: 1 2

Related biology news :

1. EMBO Gold Medal 2004 goes to Spanish scientist
2. DNA lends scientists a hand, revealing new chemical reactions
3. UCSF scientist Joe Derisi named MaCarthur Fellow
4. Conference at UH opens doors for new scientists, engineers
5. Wisconsin scientists develop quick botox test
6. UCI scientists successfully target key HIV protein; breakthrough may lead to new drug therapies
7. Alaska scientists find Arctic tundra yields surprising carbon loss
8. DuPont scientist named one of the worlds top young innovators by MITs Technology Review Magazine
9. UAF scientists discover new marine habitat in Alaska
10. Information system to help scientists analyze mechanisms of social behavior
11. White House to honor UNC School of Medicine scientist for early career achievement

Post Your Comments:
(Date:10/30/2014)... therapeutics present unique challenges when it comes to ... harm. New consensus guidelines for toxicity testing that ... characteristics of these novel biopharmaceuticals are presented in ... from Mary Ann Liebert, Inc. publishers . ... Nucleic Acid Therapeutics website until November 30, ...
(Date:10/30/2014)... Oct. 29, 2014  Securus Technologies, a ... technology solutions for public safety, investigation, corrections ... deployed exciting enhancements to its THREADS™ product, ... provide actionable intelligence and focused leads for ... drive technological innovation through identifying and delivering ...
(Date:10/29/2014)... Beaverton, OR) New research presented at the ... in Houston, TX showed for the first time ... in women using a readily available nutritional supplement, ... by Dr. Judith A. Smith, Pharm.D., associate professor ... Sciences at The University of Texas Health Science ...
Breaking Biology News(10 mins):New guidelines for reproductive & developmental toxicity testing of oligonucleotide drugs 2Securus Technologies Adds Advanced Features to Its Industry-Leading Investigative Analytics Product 2HPV infections in women eradicated by AHCC, Japanese mushroom extract 2
(Date:10/30/2014)... , Oct. 30, 2014  Regado Biosciences, Inc. ... will hold a conference call and live audio webcast ... to discuss its third quarter 2014 financial results. ... call by dialing (888) 347-1165 for domestic callers or ... be webcast live under the investor relations section of ...
(Date:10/30/2014)... (Oct. 29, 2014) – The severe flooding that devastated ... been less destructive if the bridges, roads and other ... new study from the University of Colorado Denver. , ... infrastructure," said Jimmy Kim, PhD, associate professor of structural ... Applied Science and lead author the study. "There is ...
(Date:10/27/2014)... October 27, 2014 The new ... Type (High & Medium), Sub-type (Primary & Secondary), ... Infrastructure & Transportation & Power Generation) - Trends ... GIS market with analysis and forecasting of the ... Data Tables with 52 Figures spread through 146 ...
(Date:10/27/2014)... TORONTO , Oct. 27, 2014 ... (OTCQB: GNBT) today announced two presentations demonstrating that ... its novel proprietary cancer immunotherapeutic AE37 vaccine correlated ... patients. The AE37 cancer vaccine is being developed ... ( www.antigenexpress.com ). The presentations are being made ...
Breaking Biology Technology:Regado Biosciences to Provide Third Quarter 2014 Financial Results 2CU Denver study says upgrading infrastructure could reduce flood damage 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 3Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 4Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 2Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 3Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 4
Cached News: